الفهرس 
Outcome of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on the Treatment of Colorectal Peritoneal Malignancy
Table of contentsOnly 14 pages are availabe for public view
 |  | from | 130 |  |  |
| | | from | 130 | | |
Abstract
Colorectal peritoneal carcinomatosis incidence is amounts to 5%- 15% for synchronous metastases. Best results are obtained for cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC).This treatment offers much better outcomes, leading to 5-year survival rates of as much as 30%-50%. This is a retrospective cohort study including all peritoneal carcinomatosis patients with a pathologically proven adenocarcinoma of primary colorectal origin underwent Cytoreductive Surgery (CRS) and Hyperthermic intraperitoneal Chemotherapy (HIPEC) at the surgical oncology department of the National Cancer Institute of Egypt (NCI-E). There were 27 patients diagnosed as peritoneal carcinomatosis of primary colorectal origin and treated with CRS and HIPEC during the period from January 2011 to December 2016. The aim of this retrospective cohort study is to review our institutional experience with all peritoneal carcinomatosis patients with a pathologically proven adenocarcinoma of primary colorectal origin who underwent CRS and HIPEC and evaluate the overall survival (OS) and disease free survival (DFS) in these patients by examining prognostic factors influencing survival